Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Galecto"},{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danish Biotech UNION Therapeutics A\/S Adds Program to Prevent COVID-19 With Intranasal Delivery of Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNI91103, Developed By UNION therapeutics A\/S, Selected as First Agent for Prophylactic Covid-19 \"protect-V\" Study in High-Risk Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"MinervaX","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"MinervaX Raises Upsized USD 57M Series B To Advance Its Novel Group B Streptococcus vAccine Through Mid-Stage Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"MinervaX"},{"company":"MinervaX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MinervaX Provides Clinical and Leadership Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"MinervaX"}]

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate

Details:

Data from topline results from Phase 2 trial demonstrated that cVLP-RBD (ABNCoV2) can boost neutralizing antibodies to levels reported to be highly efficacious against SARS-CoV2, irrespective of type of vaccine previously received, or initial level of neutralizing antibody.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: cVLP-RBD

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial

Details:

Data from the remaining two groups are now available, confirming the ability of cVLP-RBD (ABNCoV2) to boost neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-2.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: cVLP-RBD

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2022

ASK
US

Upload
your Pipeline Activity

Galecto

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Details:

Patients treated with GB0139 had a significantly greater rate of decline in oxygen requirement versus standard of care alone and showed other signs of reduced organ damage.

Lead Product(s): GB0139

Therapeutic Area: Infections and Infectious Diseases Product Name: GB0139

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Details:

Company reported that MVA-BN RSV had met its primary endpoint in a Phase 2 human challenge study, demonstrating a statistically significant reduction in viral load in vaccinated versus control treated volunteers.

Lead Product(s): MVA-BN

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 06, 2021

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate

Details:

Company's non-adjuvanted COVID-19 vaccine candidate cVLP-RBD (ABNCoV2), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodies.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: cVLP-RBD

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 05, 2021

ASK
US

Upload
your Pipeline Activity

MinervaX

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MinervaX Provides Clinical and Leadership Update

Details:

Group B Streptococcal vaccine based on traditional capsular polysaccharide (CPS) conjugate technology consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.

Lead Product(s): GBS-NN

Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 07, 2021

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Details:

ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac using their proprietary capsid virus like particle (cVLP) technology.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 23, 2021

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UNI91103, Developed By UNION therapeutics A/S, Selected as First Agent for Prophylactic Covid-19 "protect-V" Study in High-Risk Patients

Details:

UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 22, 2021

ASK
US

Upload
your Pipeline Activity

MinervaX

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MinervaX Raises Upsized USD 57M Series B To Advance Its Novel Group B Streptococcus vAccine Through Mid-Stage Clinical Trials

Details:

Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.

Lead Product(s): GBS-NN

Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Sanofi

Deal Size: $57.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing December 15, 2020

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Danish Biotech UNION Therapeutics A/S Adds Program to Prevent COVID-19 With Intranasal Delivery of Niclosamide

Details:

Niclosamide based nasal spray (UNI91103) will first be investigated in high risk patients to test its ability to prevent infection with COVID-19 and to reduce the severity of the disease for those already infected.

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY